Literature DB >> 15688959

Isolation and identification of neo-clerodane diterpenes from Ajuga remota by high-performance liquid chromatography.

Josep Coll1, Yudelsy Tandrón.   

Abstract

In order to explore the suitability of reversed-phase HPLC for the rapid isolation, identification and semi-preparative fractionation of neo-clerodane diterpenes from Ajuga remota, an extract from aerial parts of the plant was examined using a C18 column with UV detection and gradient elution with water:methanol. In addition to the known diterpenes ajugarins I, II, IV and V and clerodin, the presence and chromatographic behaviours of ajugapitin, dihydroajugapitin, dihydroclerodin and deacetylajugarin IV, not previously isolated from A. remota, were established. Presence of the epimeric mixture of 14-hydro-15-hydroxyclerodin (scutecyprol A) was also demonstrated together with that of 14-hydro-15-hydroxyajugapitin, the latter only in trace amounts. The structures of all isolated diterpenes were determined from NMR data. The anti-feedant activities of the isolated compounds against Spodoptera littoralis are also reported here.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15688959     DOI: 10.1002/pca.812

Source DB:  PubMed          Journal:  Phytochem Anal        ISSN: 0958-0344            Impact factor:   3.373


  3 in total

1.  In vivo antiplasmodial activity and toxicological assessment of hydroethanolic crude extract of Ajuga remota.

Authors:  Aschalew Nardos; Eyasu Makonnen
Journal:  Malar J       Date:  2017-01-13       Impact factor: 2.979

2.  Antidiabetic activity and phytochemical screening of extracts of the leaves of Ajuga remota Benth on alloxan-induced diabetic mice.

Authors:  Tadesse Bekele Tafesse; Ariaya Hymete; Yalemtsehay Mekonnen; Mekuria Tadesse
Journal:  BMC Complement Altern Med       Date:  2017-05-02       Impact factor: 3.659

Review 3.  Medicinal Plant Extracts Evaluated In Vitro and In Vivo for Antidiabetic Activities in Ethiopia: Bases for Future Clinical Trials and Related Investigations.

Authors:  Berhan Begashaw Yikna; Awgichew Shewasinad Yehualashet
Journal:  Evid Based Complement Alternat Med       Date:  2021-09-04       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.